The regulatory pathway for biological products is fundamentally different from that for small molecule drugs — and significantly more complex. Biologics, including monoclonal antibodies, therapeutic proteins, vaccines, and gene therapies, are derived from living systems and are inherently more variable,
Getting a drug approved is a monumental achievement — but it is not the end of the regulatory journey. In fact, for many pharmaceutical companies, the post-approval phase represents the longest and most complex period of regulatory engagement in a
In pharmaceutical regulatory affairs, few documents carry as much weight as the Chemistry, Manufacturing and Controls (CMC) section of a marketing authorization application. Known in the Common Technical Document (CTD) format as Module 3, this section forms the technical foundation
